Thank you for subscribing!
Finfeed Archived Nov 13, 2018
Clinical stage immuno-oncology company, Imugene Limited (ASX:IMU), today announced preparations are underway to begin the Phase 2 study of its HER-Vaxx cancer vaccine in gastric cancer patients in early 2019.
Next Investors Archived Nov 13, 2018
Imugene (ASX:IMU) is a clinical stage life sciences company on the cutting edge of this very field and is developing vaccines to boost and direct the immune system to target and attack cancer cells.
Finfeed Archived Nov 01, 2018
Race Oncology (ASX:RAC) has come to agreement with Biosynergy to pursue licensing deals for chemotherapy drug, Bisantrene.
Next Investors Archived Oct 30, 2018
Today’s biotech junior is in the business of repurposing late-stage drug assets that have been overlooked by big pharma.
Get expert stock analysis direct in your inbox
Finfeed Archived Oct 29, 2018
Clinical-stage oncology company, Prescient Therapeutics Ltd (ASX:PTX), has appointed leading drug discovery and development executive, Dr James Winkler, as Vice President for business development based in the US.
Finfeed Archived Oct 17, 2018
The biotech sector was yesterday led by biopharmaceutical drug discovery and development company, Antisense Therapeutics (ASX:ANP) which ended the day 217% higher.
Finfeed Archived Oct 03, 2018
There are few companies dealing in nanotechnology in Australia, fewer still in the biotech space, which could make this a unique investment sector if investors are so inclined.
Finfeed Archived Sep 07, 2018
The ethics of big pharma are debatable and deserve a long-form serious analysis, so let’s avoid the debate for now and look at the good work small biotech companies are doing.
Finfeed Archived Sep 03, 2018
Prescient Therapeutics Ltd (ASX:PTX) has today advised it has identified an improved manufacturing route for PTX-100 for use in its upcoming pharmacokinetic (PK) and pharmacodynamic (PD) clinical trial.
Join Our Mailing List
